Anti-CD27 antibodies and use thereof
US11795230B2 · kind B2 · utility
0Cited by
3References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 13, 2018 |
| Grant date | Oct 24, 2023 |
| Priority date | — |
| Expiry date | Dec 14, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides an antibody, or an antigen binding fragment or variant thereof, which binds to CD27 and exhibits at least one of the following properties: specifically binds to CD27 with a KD of 10−8 M or less; activates and/or increases CD27 mediated NF-κB activity; stimulates CD4+ and/or CD8+ T cell proliferation; binds to human CD27 expressed on a cell surface; stimulates secretion of IFN-γ by CD4+ and/or CD8+ T cells. The present disclosure also provides a method for preparing and using said antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.